BIO
Bio-Rad Laboratories A·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 4
MACD Death Cross
Bearish Engulfing
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BIO
Bio-Rad Laboratories, Inc.
A manufacturer of products for the life science research and clinical diagnostic markets
Life Science Tools and Services
--
10/24/2008
New York Stock Exchange
7,700
12-31
Common stock
1000 Alfred Nobel Drive, Hercules, California 94547
--
Bio-Rad Laboratories, Inc., was founded in 1952 and established as a company in 1957. It was early devoted to the research and production of specialty chemicals for use in biochemistry, pharmaceuticals and other life science research applications. It entered the field of clinical diagnostics with the development of its first technology separation suite and life science research materials. Through internal R&D efforts and decisions, it has expanded to different markets. Now, Bio-Rad offers a range of products for life science research, healthcare, analytical chemistry and other market production.
Earnings Call
Q3/2025
Estimate EPS1.93
Actual EPS2.26
Estimate Revenue651.30M
Actual Revenue653.00M
Bio-Rad's Q3 2025: Contradictions Emerge in Process Chromatography, Diagnostics, Tariff Impact, Digital PCR, and China Market Outlook
Oct 29,2025 08:48
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
BIO has released its 2025 Q3 earnings. EPS was reported at 2.26, versus the expected 1.93, beating expectations. The chart below visualizes how BIO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BIO has released its 2025 Q3 earnings report, with revenue of 653.00M, reflecting a YoY change of 0.51%, and net profit of -341.90M, showing a YoY change of -152.34%. The Sankey diagram below clearly presents BIO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
